insights_auto
Why is MVIR down 4.39%?
Dive Deeperchevron_right
MVIR:STO
Medivir AB
SEK 1.61
arrow_downward
-4.39%(-0.074) 1D
Oct 5, 4:31:27 PM GMT+2 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for MVIR...
Open
SEK 1.67
High
SEK 1.67
Low
SEK 1.60
Mkt. cap
1.00B
Avg. vol.
1.76M
Volume
1.65M
52-wk high
SEK 2.88
52-wk low
SEK 0.34
EPS
-SEK 0.37
Shares outstanding
624.18M
No. of employees
6
Open
SEK 1.67
High
SEK 1.67
Low
SEK 1.60
Mkt. cap
1.00B
Avg. vol.
1.76M
Volume
1.65M
52-wk high
SEK 2.88
52-wk low
SEK 0.34
EPS
-SEK 0.37
Shares outstanding
624.18M
No. of employees
6
News stories
From web sources and news partners
Investing.com
·
9 minutes ago
Dow Jones squeezed at 51,328 with bears in control: Live levels
TradingView
·
53 minutes ago
The Dow Jones Index Opens 0.31% Lower
Altcoin Buzz
·
2 hours ago
Kalshi Gets CFTC Approval for S&P 500 Perpetual Futures
FXEmpire
·
1 hour ago
Dow Jones Forecast: Treasury Yields Put 50,000 Support at Risk
Profile
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
About Medivir AB